OncoMatch/Clinical Trials/NCT07154264

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Is NCT07154264 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including DZD8586 and Venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma.

Phase 2RecruitingDizal (Jiangsu) Pharmaceutical Co., Ltd.NCT07154264Data as of May 2026

Treatment: DZD8586 · Venetoclax — This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.

Check if I qualify

Extracted eligibility criteria

Cancer type

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any previous or current treatment

Any of previous or current treatment prohibited by protocol

Lab requirements

Blood counts

adequate bone marrow reserve

Kidney function

adequate organ functions

Liver function

adequate organ functions

Adequate bone marrow reserve and organ functions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify